



OCCASION

This publication has been made available to the public on the occasion of the 50th anniversary of the United Nations Industrial Development Organisation.

TOGETHER

for a sustainable future

DISCLAIMER

This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as "developed", "industrialized" and "developing" are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO.

FAIR USE POLICY

Any part of this publication may be quoted and referenced for educational and research purposes without additional permission from UNIDO. However, those who make use of quoting and referencing this publication are requested to follow the Fair Use Policy of giving due credit to UNIDO.

CONTACT

Please contact <u>publications@unido.org</u> for further information concerning UNIDO publications.

For more information about UNIDO, please visit us at <u>www.unido.org</u>

D/222 (D/WG.271/6)





UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION

REPORT OF THE TECHNICAL CONSULTATION ON PRODUCTION OF DRUGS FROM MEDICINAL PLANTS IN DEVELOPING COUNTRIES

Lucknow, India, 13-20 March 1978 //

001020

*This was not one of the Consultations called for in persgraph \$1 (d) of the Lime Declaration and Plan of Action and should not be confused with any of the "Consultation Meetings" organized by UNIDO in response to that call.

CONTENTS

-

Chapter		Page
	INTRODUCT ION.	4
	RECOMMENDATIONS.	5

Part one. Report of the meeting

I.	ORGANIZATION OF THE MEETING	9
II.	SUMMARY OF DISCUSSION	9
III.	COMPILATION OF LISTS OF MEDICINAL PLANTS	12
	Part two. Summaries of technical papers	
07400	An integrated approach to research on medicinal plants N. Anand	14
07963	Medicinal plants for ouring diseases other than communicable tropical and infectious F. Sandberg	14
07883	Plants of the African pharmacopoeias used in the treatment of tropical diseases J. Kerharo	14
07884	Industrial requirements for processing medicinal plants B. Bombardelli	15
	Drugs derived from medicinal plants Secretariat of the United Nations Industrial Development Organisation	16

Part three. Summaries of country and other papers

Algeria	17
Burma	17
Ouba	18
India	18
Madagascar	18
Nexico	19
Nepal	19
Pakistan	19
Revanda	20
Thailand	20
Other papers	21

Amerone

I.	Biologically active plants considered during the technical con- sultation	23
II.	Additional list of plants used mainly in traditional medicine in Africa, Asia and Latin America	26
III.	Important plant drugs suitable for production by developing countries	32
IV.	Other plants of economic importance and export potential	36
٧.	Biologically active plants for which drug development has reached an advanced stage	37
VI.	The important excipients	38
VII.	Facilities available in various countries	39
VIII.	List of documents	42
IX.	A model unit for the preparation of orude extracts	43
x.	National Information Centre for Drugs and Pharmaceuticals (NICDAP)	45

Page

.

INTRODUCTION

At several UNIDO meetings on pharmaceuticals, the developing countries have expressed a strong wish for the promotion, development and production of drugs derived from medicinal plants, so as to enable them to utilize their own resources, economize on foreign exchange and become self-sufficient and self-reliant in that field of pharmaceuticals.

In pursuit of those aims, UNIDO organized a workshop, called the Technical Consultation on the Production of Drugs from Medicinal Plants in Developing Countries, under the joint auspices of UNIDO, the Government of India and the Central Drug Research Institute of India (CDRI), at Lucknow, India, from 13-20 March 1978. Background papers were prepared by UNIDO consultants and reviewed at UNIDO headquarters at Vienna. A paper prepared by the UNIDO secretariat provided the guidelines for the formulation of a plan of action for the sector. Experts from various countries were also requested to prepare country papers on the status of production and use of drugs from medicinal plants in their countries.

RECONDENDATIONS

1. A number of essential drugs used in modern medicine can be produced from medicinal plants available in developing countries. Priority in the production of drugs derived from medicinal plants should be given to drugs that are well accepted and widely used (listed in annex I and III).

2. In the cultivation of medicinal plants, priority should be given to the plants identified by UNIDO.

3. Developing countries should be helped by UNIDO to start the production of products based on indigenously available/cultivated plants to meet demand within the country and also for export.

4. The technological status of different developing countries varies greatly; some countries have practically no industry and cannot easily obtain the solvents required for extraction, while other have a reasonably well established phytochemical industry. Countries in the first category could make a start by setting up units for the preparation of crude extracts for domestic use and for export. The production units should have well-equipped quality control laboratories attached to them. Even small units able to process one ton of raw material a day would be of economic benefit. (See annex IX for a desoription of such a unit.) Countries that already have a reasonably well established phytochemical industry could set up more sophisticated production plants. UNIDO should assist in the transfer of technology and supply of equipment, if required.

5. The training of personnel is important, and UNIDO should organize training programmes for individual countries or groups of countries on the cultivation of medicinal plants, the setting up of pilot plants and production units, the quality control of products, and pharmacological screening. One training centre could be located at Lucknow to take advantage of the facilities available at the Central Drug Research Institute of India and the Central Indian Medicinal plants Organization (CIMPO). Mobile units could also serve a useful purpose by training personnel directly within the country itself. The technical co-operation between Developing countries (TCDC) training programme could also be very useful, and UNIDO should make efforts to organize such programmes. 6. Developing countries that have a variety of important plants, for which there is a demand on the international market (see annex IV), should be assisted to process those plants into semi-finished form for export. Detailed market studies must be made, however, so as to avoid creating a glut on the market.

7. The use of pure active principles as medicaments may be discouraged wherever total extract can be used, depending on pharmacological evidence. The effect of this would be to bring down the price of the medicaments.

8. The foreign exchange budgets of some developing countries are limited and it is difficult for them to allocate funds for the establishment of production units that require foreign exchange. UNIDO should allocate funds for the least developed countries from its own resources, UNDP grants or outside donations for the purpose so as to accelerate the development of the medicinal plant industry.

9. UNIDO should prepare detailed techno-economic reports for small multipurpose production units to process medicinal plants. The reports should cover sources of technology, the minimum economically viable plant size, raw materials required, equipment, investment, and markets.

10. UNIDO should establish an information centre for drugs derived from medicinal plants and should inform developing countries of progress made. This centre could be the National Information Centre for Drugs and Pharmaceuticals (NICDAP) already established at CDRI. Co-operating countries and UNIDO could send information to NICDAP, and the information could then be disseminated widely. (A description of NICDAP is in annex X.)

11. It would be useful if UNIDO could establish a budget for the purchase of technology for the production of drugs from medicinal plants and by synthesis, and could make the technology available to the developing countries interested in it.

12. UNIDO, through its chemical industry programme, should help to make available the solvents and materials needed for the production of pharmaceuticals so as to promote the local production of drugs.

13. One of the problems of an industry processing medicinal plants is to ensure a regular supply of such plants. Some of them grow wild, but many others need to be cultivated. UNIDO, in co-operation with FAO, could help by making arrangements for the supply of planting materials of the right quality, and

- 6 -

agro-technology, if required, although the help needed for promoting cultivation would have to be provided by the Government of each country. The developing countries might consider setting up a separate organization for promoting the cultivation of medicinal plants on the lines of CIMPO. Such an agency could make planting material available to the cultivators, and provide the agro-technological package and other inputs. It could also help in carrying out market surveys and buying the plants from the cultivators and supplying them to the appropriate agencies for production or export.

14. Developing countries have a rich flora that is a potential source of new drugs and new biologically active substances. A co-ordinated effort is needed to exploit that vast resource. Although each country should set up its own research laboratories for the biological evaluation of its own plants, UNIDO could help to co-ordinate the efforts. Some of the smaller countries may not be able to set up research laboratories for wide-range pharmacological screening. Such countries could start by making extracts, and use for screening the facilities of well-established institutions such as CDRI, the Instituto Mexicano para el Estudio de Plantas Medicinales, the Fangladesh Council of Scientific and Industrial Research Laboratories, and the Pakistan Government Institute of Chemistry.

15. The developing countries should be careful, when using their medicinal plant resources, not to disturb the ecological balance. They should take steps to conserve and preserve the germ plasma available and also their fores: wealth. Many of those resources will be needed by the drug industry for many years to come.

16. Many of the developing countries have their own traditional systems of medicine, and large segments of their populations still depend upon traditional remedies. Efforts should be made to include traditional remedies in health care programmes in those countries. To that end:

(a) The production of established traditional remedies should be taken up by centralized agencies, with proper quality control of the product;

(b) In order to ensure the safety of drugs that are going to be used for long periods, studies should be made of their sub-acute and chronic toxicities;

(c) Remedies whose use is not yet well established should be subjected to direct clinical trials to establish their efficacy;

(d) For the scientific production of traditional remedies, proper practices must be established for the cultivation, storage, and processing of plants, and analyses of the medicaments made from them; (e) Herbal remedies whose usefulness has been established by pharmacological, clinical and toxicological studies should, after approval by the Departments of Health of each country, be made part of medical college courses;

(f) Remedies for which claims need to be verified experimentally should be tried on animals in the form they are used in the traditional system of medicine;

(g) UNIDO should help to organize facilities for proper clinical evaluation, pharmacological screening and the development of technology in countries that lack such facilities.

17. An advisory board of five experts representing different aspects of the phytochemical industry should be constituted by UNIDO to evaluate the prospects for increasing the production of crude drugs, initially in South-East Asian countries, and subsequently in African and Latin American countries. The advisory board should also draw up a master plan for phytochemical research and development.

18. UNIDO should play a leading role in mobilizing the developing countries to produce drugs from medicinal plants and should take measures to accelerate the establishment of production units in those countries. The programme of technical co-operation between developing countries organized and financed by UNIDO can play an important part in the achievement of this objective. Such efforts would help developing countries with their expanded national health programmes, improve their economies and create employment opportunties.

Part one. Report of the meeting

I. ORGANIZATION OF THE MEETING

The Director and Chairman of the meeting was A. Tcheknavorian, Chemical Industries Section, Industrial Operations Division, UNIDO. Two meetings were held each day. The programme of activities included the following:

Presentation and discussion of submitted technical and country papers Compilation of lists of medicinal plants

Visits to establishments concerned with medicinal plants in Bangalore and Bombay

Consideration and adoption of the final report and recommendations

The opening formalities of the meeting including an address by S. Krishnashramy, Secretary to the Government of India, Ministry of Chemicals and Fertilizers, who underlined the significance of medicinal plants in countries where modern medicines were often available to less than a quarter of the population.

II. SUMMARY OF DISCUSSION

A general discussion followed the presentation of papers. It was agreed that countries that grow medicinal plants should be encouraged to go ahead with the production of drugs that clinical evidence had shown to be effective. The group also agreed that the production level for each country would depend on its infrastructure, the plants it had available and the state of its technology. Developing countries were classified into three groups:

(a) Those with no facilities for research and development, pilot plants or industrial production;

(b) Thuse with facilities only for the preparation of extracts of medicinal plants;

(c) Those with facilities for pilot plants or the industrial production of active principles from medicinal plants.

All participants were of the opinion that, although UNIDO should emphasise the need for the production of plant drugs used in both the traditional and the modern systems of medicine, it should give immediate attention to plant

- 9 -

products that were accepted in modern medicine, were widely used in health programmes or were of large economic value. UNIDO could assist the developing countries by making available technology, training personnel, and making market studies in collaboration with other United Nations agencies. It could also help with the design of plants, and in developing methods of quality control and standardization of products for local use and export. It was suggested that, in order to facilitate and accelerate the establishment of a pharmaceutical industry based on medicinal plants, the developing countries should be urged to co-operate with each other on the transfer of technology. the training of technical personnel and the supply of equipment and planting material. Countries that did not even produce total extracts of plants should be assisted in the setting up of production units to do so. Countries that wished to process extracts further and produce pure active principles but did not possess the necessary technology; might be helped by UNIDO to acquire it. It was pointed out that the production processes for most of the important plant products were not covered by patents; so patents would not be a barrier to production. It was the general opinion that medicinal plants for which there was an international demand should not be exported by the producing country in the form of raw plant material, but could be processed further. The export of a semi-finished product would give the benefit of added value and would create additional employment opportunities in small industry. However, the export of plants and plant products would need to be organized so as not to create a glut on the market. A detailed techno-economic and market study should therefore be carried out to assess real market requirements.

It was pointed out that an industry for the production of drugs from medicinal plants, whether for local use or for export, could be successful only if the quality of the products conformed to specifications. A wellequipped quality control laboratory was, therefore a basic requirement for a production unit. Adequate quantities of good quality raw materials must also be available; so the cultivation, collection and storage of plant materials would have to be organized before production units were established. As regards the cultivation and availability of plant material, it was suggested that UNIDO, in co-operation with FAO and the agriculture and forest departments of each country, might carry out studies to establish the most appropriate methods of cultivation of important medicinal plants, estimate the availability

- 10 -

of plant material, and determine the most suitable soil and climatic conditions for the cultivation of various plants in different regions. The success of the mobile unit mission organized by UNIDO for the production and quality control of extracts of medicinal plants in Africa and Asia had confirmed that such missions were an appropriate means of transferring technology for the production of extracts and training personnel in production and control methods in countries without experience in them. The investment in such a mobile unit, which could be taken to remote areas where the plants were grown, was estimated to be about \$US 80,000.

Control of production of opium

It was suggested that, in view of the abuse of opium, the production of morphine and codeine from poppy capsules and straw should be promoted, and the preparation of opium be discouraged and put under stricter control. Simultaneously, efforts should be made to suggest alternative crops for opium poppy cultivators and to develop new substitutes for morphine and codeine.

Joint pricing policy for medicinal plants

To ensure the continued cultivation of medicinal plants in the developing countries, the prices should be remunerative for the farmer. Participants expressed the opinion that UNIDO should therefore encourage the establishment of international agencies that would buy the raw plant material from the individual countries and prevent unhealthy competition between grower countries.

Establishment of regional research and development centres

The establishment of research and development facilities was expensive and required skilled personnel, and might be beyond the immediate capacity of individual developing countries. It was therefore suggested that use should be made of existing research and development centres in the regions, strengthening them, where necessary, so as to enable them to cater to regional needs until national facilities could be established. The centres could concentrate on the screening of plants for therapeutic groups for which plant drugs were not available and also on the development of plant cultivation and processing technology. (For 3 list of some of the centres see annex VII.)

- 11 -

Availability of planting material

In order to promote the cultivation of medicinal plants, it was necessary to make available suitable planting materials that some countries had difficulty in obtaining. Participants felt that UNIDO could play an active role in that area.

Manufacturing technology

A UNIDO secretariat paper on the technology of the manufacture of drugs from plants outlined the various extraction methods that could be used. The representative of the UNIDO secretariat said that, in order to make a comprehensive plan based on important plants identified at the Meeting, arrangements would be made for the preparation of detailed reports on technical and other matters, including equipment, source of technology, raw materials required, the economic unit for production, the investment cost of production, and market potential.

A model unit for the preparation of crude extracts is shown in annex IX.

III. COMPILATION OF LISTS OF MEDICINAL PLANTS

The primary objective of UNIDO in organizing the Meeting was to identify essential drugs derived from medicinal plants that are widely used and for the production of which technology is available. In order to achieve that objective, the following lists were compiled:

(a) A list of the medicinal plants found in various regions (Africa, Asia and Latin America) whose active principles are used in modern medicine (annex I), and an additional list of plants used mainly in traditional medicine in Africa, Asia and Latin America (annex II);

(b) A more restricted list of the plants that are more widely used for the production of medicines, classified by therapeutic group (the WHO essential drug list was used as a guide) (annex III);

(c) A list of plants that are not necessarily used as drugs but are the source of products used in the pharmaceutical industry and for which there is a demand on the international market (annex IV). Such plants should be cultivated and processed into semi-finished form for export;

(d) A list of plants on which research and development is well advanced in various countries and that are likely to be introduced into clinical practice (annex V);

(e) A list of commonly used excipients (annex VI).

In order to promote the production of finished formulations from active principles, and to keep their price within the reach of ordinary people, steps should be taken to make the excipients used in the formulation available at reasonable prices. To keep the cost of treatment low, total extracts can be used in place of pure active principles in most cases, if pharmacological evidence indicates that it is possible to do so.

As the use of traditional medicines is quite widespread in most of the developing countries, particularly in rural areas, there is a need to evaluate their safety and ensure quality-control standards of the products at every stage, including cultivation, storage and handling of the plants. Modern scientific inputs are therefore needed.

In the light of the foregoing, steps should be taken to encourage the developing countries to produce and use drugs derived from medicinal plants. To do so would have the following advantages:

(a) The foreign exchange required to import such drugs would be saved;

(b) The export of raw plant material would be discouraged, and the export of processed products encouraged, which would earn more foreign exchange;

(c) More effective use would be made of the knowledge of traditional systems of medicine that already cater to large segments of the population in developing countries;

(d) Natural vegetable resources would be utilized;

(e) Industrialization would be promoted;

(f) The appropriate technology for the developing country would be developed;

(g) Farmers' income would be augmented.

Part two. Summaries of technical papers*

An integrated approach to research on medicinal plants

N. Anand

Large sections of the population of the developing countries still depend on traditional systems of medicine, the cost of which is relatively low. Traditional remedies should therefore be included in the health care programmes of those countries. The measures needed to do .hat are: (a) standardisation of the production and quality control of important medicaments, (b) evaluation of the safety of drugs that have to be administered for long periods, (c) direct olinical evaluation of less commonly used drugs, and (d) broad-spectrum biological screening of drugs or plants for which the evidence as to their therapeutic activity is insufficient or doubtful.

Since plants are an important renewable source of drug intermediates and other chemicals of economic value, their cultivation, and production of their active constituents, would be of great benefit to the developing countries and should be promoted. About twenty such plants have been identified.

Medicinal plants for curing diseases other than communicable tropical and infectious

F. Sandberg

The paper discusses the origin, therapeutic use, and form of application of each of a number of plants, together with their market prospects and the technology for processing them.

Plants of the African pharmacopoeias used in the treatment of tropical diseases

J. Kerharo

Many tropical diseases belong to well established nosological groups. The classification adopted, in accordance with tropical pathology data, therefore reviews in order the treatment of ailments due to protozoan helminths,

*The titles of those with documents symbols are listed in annex VIII.

spiroohaetes, viruses, microbes, and deficiencies, and the treatment of miscellaneous ailments. The therapeutic indications and uses of 159 plants are given. A number of varieties already used in modern medicine or meriting priority attention are singled out?

> <u>Plant</u> <u>Cucurbita</u> <u>maxima</u> <u>Cucurbita</u> <u>pepo</u> <u>Chenopodium</u> <u>ambrosoides</u>

Euphorbia hirta

Holarrhena floribunda

Strophanthus sarmentosus <u>Caloncoba echinata</u> <u>Caloncoba welwitschii</u> <u>Centella asiatioa</u> <u>Fagera santhoxyloides</u> <u>Guiera senegalensis</u> Helminthiasis Nematodiasis Amoebiasis Asthma Amoebiasis Trichonomiasis

Disease used against

Trachoma

Taeniasis

Leprosy Dermatitis

Drepanocytosis Choleriform diarrhea

The paper concludes with the suggestion that the development of appropriate pharmaceutical technology based on the use of local drugs could improve the well-being of the people of developing countries that are short of medicaments.

Industrial requirements for processing medicinal plants

E. Bombardelli

A survey of the main technologies for the preparation of natural products of vegetable origin is preceded by some considerations of the current situation and general market trends. The most important phases of the preparation of any product, whether extract or pure compound, are examined, from drug grinding to the final phases of purification. The choice of solvent and the type of extractor to be used depends on the technical information of the most important plants. A typical scheme for processing and a few examples of preparation of some extracts illustrate the technology involved.

Drugs derived from medicinal plants

Secretariat of the United Nations Industrial Development Organisation

• The paper stresses the importance of the production and use of drugs derived from medicinal plants in the developing countries and the role played by UNIDO in this field. UNIDO feasibility studies on medicinal plants, in several developing countries show that the laok of organization for the cultivation and collection of the plants, transport, suitable technology, market information, financial resources, skilled personnel, and research facilities hinder the commercial exploitation of medicinal plants. In order to encourage co-operation between developing countries, UNIDO has developed regional projects in countries of the Sahara, South-East Africa and Asia. It also organized mobile units in Africa in 1977 for extraction, distillation, and process control and testing. A mobile unit mission is being organized for Asia in 1978.

Part three. Summaries of country and other papers

Algeria

Algeria, because of its geophysical and climatic conditions, has more than 500 varieties of medicinal plant. More than half are used in traditional medicine; many are aromatic plants that are of interest to the perfume industry. Scientific studies should be made of plants that are regularly used in traditional medicine, and also of related varieties already used in the pharmaceutical industry, so as to establish their properties before their use is promoted.

Burma

In Burma, the development of plant materials as a source of medicines and the promotion of drugs from medicinal plants for national health care are approached in the following manner.

First and foremost, the relevant departments were organized with an overall authority to co-ordinate their activities. The Burmese Central Research Organization, which was formed to identify and test-cultivate medicinal plants has identified 700 medicinal plants during the 20 years of its existence.

The Burma Medical Research Institute is concerned with the biological screening and pharmacological testing of medicinal plants and indigenous medicines. Here, care is taken to differentiate between the principles and methodology of modern and traditional medicines.

An organization under the industries department is responsible for medicinal plant cultivation. Much pioneering work, such as extension services and incentive schemes for farmers, is necessary. Choice of the right type of species, soil and climatic conditions is also essential.

The state pharmaceutical industry has facilities for the extraction and formulation of galenicals. Various hospital pharmacies under the public health department are capable of compounding and formulating indigenous drugs. Though quality control can be exercised for modern herbal drugs, the same does not apply to traditional drugs as yet, as the use of complex mixtures makes standardization difficult. The various indigenous medical clinics stationed throughout the country provide appropriate channels for the distribution of official traditional drugs, although there are many privately manufactured drugs that remain to be examined. Some of these have been tested by the National Health Laboratory and found to be free of toxic effects.

Last but not least is the medical education system. In 1970 an Institute of Indigenous Medicine was established with the aim of producing qualified traditional practitioners who can prescribe traditional drugs to patients with more confidence.

Cuba

Cuba possesses an abundant medicinal flora, and numerous plants are in use at present.

The Experimental Station of Medicinal Plants was established in 1973 to study the cultivation conditions of the plants and also their botanical and genetic characteristics.

India

As a result of research and development carried out during the last 25 years, India has developed a prosperous medicinal plants industry. At present, India produces substantial quantities of crude drugs and active constituents and is one of the leading exporters of crude drugs and active constituents from plants. Medicinal plants produced in India are either collected from wild sources or cultivated in various parts of the country. The paper lists some of the most important plants that are collected from the forests or cultivated, and other that are being cultivated on an experimental scale.

Research on the use of tissue culture for the propagation of medicinal plants included work on <u>Dioscorea</u> sp., <u>Solanum</u> sp., Costus, <u>Rauwolfia</u> <u>serpentina</u> and <u>Atropa belladonna</u>. The work was taken up to the pilot-plant stage. Significant results were obtained with simple ingredients. A scheme is being devised to extend the work to commercial cultivation.

Madagasoar

In view of Madagascar's rich and varied flora, it is not surprising that the traditional pharmacopoeia should have been taken as the basis for research to find new medicaments. A number of active principles have been isolated since the 1950s. The National Pharmaceutical Research Centre has been set up to review the pharmacopoeia and it is hoped that many other plants will be used by the pharmaceuticals industry.

Mexico

The Mexican Institute for the Study of Medicinal Plants (IMEPLAM) suggests that there should be an international data bank on medicinal plants to gather ethnobotanical, historical and anthropological information. Lists of plants cultivated should be exchanged by medicinal plant institutions in developing countries.

Pharmacological testing should establish the strategy for any chemical work.

Work should be done on plants for which there is ethnobotanical, historical and anthropological information, in preference to plants for which there is no background information.

Nepal

Many kinds of important herbal plants grow in the tropical, subtropical, temperate and alpine regions of Nepal, which exports plants worth over 20 million rupees (\$US 1.6 million) a year all over the world. Besides 82 Ayurvedic Centres, there are 65 health posts where modern medicines are stocked. Fifteen Ayurvedic preparations are dispensed to combat common diseases. The author gives a list of 62 medicinal plants used in Ayurvedic preparations and included in other pharmacopoeias. The department of medicinal plants, which is a research organization, is responsible for the botanical survey and herbarium, herbal forms, the royal botanical garden, and the royal drug research laboratory.

Research is needed on traditional medicines, such as "silajit" for curing infective hepatitis, to obtain the effects desired.

Pakistan

The main obstacles to the wider cultivation and greater use of medicinal plants in Pakistan and other developing countries are:

(a) The lack of information on future international demand for various medicinal plants;

(b) The lack of feasibility studies and long-term forecasts based on current international prices and future development trends; (o) The lack of detailed information about optimum conditions of growth (soil conditions; optimum time of planting and harvesting; fertilizers, insecticides and fungicides required; the most suitable monitoring procedures for assaying the percentage of active consituents at various stages of growth;

(d) The lack of knowledge of the most feasible processing technology for the isolation and separation of active constituents on various scales.

The integration of traditional systems of medicine and modern medical practices can be brought about by authenticating each herbal prescription after pharmacological, clinical and toxicological studies and including information about useful and authenticated herbal remedies in the courses of various medical colleges.

Rwanda

The research in laboratories in Rwanda follows a rational path: ethnobotanical screening, phytochemical screening, pharmacological screening, toxicological screening, and the production of drugs. Local plants listed in the various pharmacopoeias, are studied first, then plants listed in the various pharmacopoeias but of different species, and finally plants used in native medicine but not listed. The author lists the plants currently used in the production of drugs.

Thailand

There are 1,066 traditional drug factories and 177 modern drug factories in Thailand. About 90 per cent of the raw materials used for traditional drugs are obtained from medicinal plants, and more than 90 per cent of the raw materials used in modern drug factories are imported. The annual consumer value of drugs on the market is estimated to be \$US 200 million. The annual export value f.o.b. of medicinal plants from Thailand is between \$US 1 million and \$US 3 million and is increasing.

Since 1940, research on indigenous medicinal plants had been done by various institutes, but was initially mostly of academic interest. By 1965, the Applied Scientific Research Corporation of Thailand (ASRCT), with financial support from the Thai Covernment and aid from UNIDO, succeeded in establishing a cooperative research programme on medicinal plants, with the aim of developing modern drugs from indigenous medicinal plants.

- 20 -

The co-operating bodies, comprising various institutes with different background experience, were able to provide the necessary project approach. Work was done on pharmacognosy, pharmacology and toxicology, chemical identification, clinical study, drug formulation, economic evaluation, and cultivation.

Other papers


Research on medicinal plants in Central and Equatorial Africa

In 1965, 196 species of medicinal plant were identified. Research work on those plants included pharmacological screening of the whole material, crude extract and specific fractions. Pronounced strong activity was shown by 129 of the plants. Work also was carried out to isolate and elucidate the molecular structure of the compounds.

UNCTAD

Assistance by ITC/UNCTAD/GATT in the establishment of a programme for medicinal plants and their derivatives could be of great value, mainly for ascertaining market demand but also for elaborating marketing strategies and development plans.

Integrated programmes involving co-operation with other international bodies, promotional actions and the establishment of contacts, would help the developing countries to formulate production plans that would make it possible to meet domestic demand for some basic medicines and expand export trade.



	Part of		Availal	<u>ility</u>		Region		Nethod of		rket	
Name of plant	the plant used	Product	Culti- vated	Wild	Africa	Latin America	Asia	produc- tion y /		Export	Trend
Acacia arabioa) Acacia senegal)	Stem	Gum		+	+				+	#	Steady
Aconitum sp.	Root	Total extract		+			+	C	+	+	Down
Acorue calamus	Rhizome	Essential oil and crude d rug		+			÷	*	+	++	Steady
Acculus hippocastanum	Seeds	Acesin and total extract	+	+			+	C	+	++	Up
Areve sizalana	Juice	Hecogenin	+		+	+	+	D	+	++	Steady
Aloe sp.	Leaf juice	Aloin	+	+	+	+	-		+	++	Steady
Anmi majus	Seeds	Xanthotoxin	+	+	+		+	Þ	+	++	Up
Ammi visnaga	Fruits	Visnagin, khellin		+	+	+		C	+	++	Steady
Amomum subulatum	Fruits	Essential oil	+	+	+		+	A	+	++	Up
Amomum xanthloides	Fruits	Escential oil	+	+	+		+	٨	+	++	ປັງ
Andira araroba	Stem wood	Total extract		+	+	+		C		+	Steady
Anethum sp.	Fruit	Essential oil	+			+	+		+	+	Steady
Anice	Fruits	Essential oil	+		+		+		++	++	Steady
Artemisia maritima	Flowering tops	Santonin		+	+		+	D	+	+	Stendy
Atropa belladonna	Leaf and roots	Total alkaloids	+				+	c	**	++	Steady
Berberis aristata	Root, stem bark	Berberine		+			+	3	+	++	Steady
Berberie asiatica	Root, stem bark	Berberine		+			+	3	•	++	Steady
Berberie lycium	Root, stem bark	Berberine		+			+	3	+	++	Steady
Betula alnoidee	Stem bark	Crude drug		+			+		+	+	Steady
Capeicum annum	Fruits	Capsaicin cleoresin	+		+	+	+	D	+	+	Stendy
Carioa papaya	Fruit juice	Papain	+		+	+	+	3,0	+	+	Up
Carum oarvi	Fruit	Essential oil	+		+		+	Å	+	++	Steady
Cassia acutifolia	Leaves and pods	Sennoeidee		+	+	+	+	c	+	++	Up
Caseia angustifolia	Leaves and pods	Sennoeidee	+				+	C	+	++	Սաթ
Cassia italica	Le aves and pod s	Sennosidee		+	+			C	+		
Catharanthus roseus	Leaves and roots	Vinblastine, vin- cristine, raubasine	+	+	•	+	+	D	+	++	Steady
Centella asiatica	Whole plant	Asiaticoeide	+	+	+		+	c	+	++	Steady
Centella acuminata	Roots	Dmetine	+			+	+	D	+	++	Up
Cephaëlis Ipecacuanha	Roots	Instine	+			+	+	D	+	++	Up
Ceratonia siliqua	Fruit	Total extract	+	+	+			¢	+	++	Steady
Chenopodium ambrogioides	Flowering top and	Escential oil									
Cinchons ep.	whole plant Stem and root bark	Quinine, quinidine	+	+	+	+	+	A D	+		Bi eady
Claviceps purpures	1000 DELK	Ergotamine, ergo- toxine, ergometrine	+	•	+	+	+	D	*	++	Up Béacht
Cola nitida	Seeds	Total extract	+		+	7	-	3		**	Steady Up
Combretum	Leaves	Total extract	+	*	-	+				++	u
micranthum				+	+		+	C	+	++	Uy

Annex I

BIOLOGICALLY ACTIVE PLANTS CONSIDERED DURING THE TECHNICAL CONSULTATION

y/ A = steam distillation; B = water extraction; C = Alcohol extraction; D = extraction with other solvente.

Annex I	(Cont*d)

	Part of the plant		Availal Culti-	<u>ility</u>		Region Latin		Nethod of produc-	Narket potential	5 m
Name of plant	used	Product	vated	Wild	Africa	America.	Asia.	tion 🖌	Local Expor	t Tren
Commiphore mukul	Resin	Gum		+			+	D	++	
Costus speciosus)	Rhizome	Diosgenin		+		+	+	D		
Cymbopogon flexuosus	Leaves	Essential oil, citral	+		+	+	+	*	+ ++	Stee
Detura sp.	Leaves	Atropine								
Derris elliptics	Rout	Rotenone	+	+	+		+	Ð	+ ++	Ŭ₽
<u>Digitalis lanata</u>	Leaves	Digoxin and lanato- sides	+		+			C,D	++ ++	Ste
Dioscorea sp.) Dioscorea Leichartii	Tubers	Dicagenin	+	+	+	+	+	D	++ ++	Ste
Duboisia monoroides	Stem	Hyosoyamine, hyoscine	+	+	+	+	+	Þ	++ ++	Ste
<u>Inheire</u> corardiana	Whole plant	1-Ephedrine		+			+	D	++ ++	Ste
Bohedre vulgaris	Whole plant	1-Mphedrine		+			+	D	++ ++	Ste
Bohedre nebrodensis	Whole plant	1-Bphedrine		+			+	D	++ ++	St
<u>Bacelyptus</u> <u>clobulus</u>	Leaves	Essential oil	+		+	+	+		++ ++	St
Glauoum flavum	Leaves	Glaucine		+	+		+	C	++ ++	5 t
Glaucoum simplex	Rhizome	Colchicine		+	+		+	D	++	
Gloriosa superbs	Rhisome	Colchicine		+	+		+	D	++ +	St
Glycyrrhize	Rhizome	Total extract		+			+	3	++ ++	51
<u>Heracleum</u> candicans	Roots	Xanthotoxin		+	+		+	3	+ ++	51
Hibisons sabdariffs	Flower	Dried flowers	+		+	+	+		+ ++	U
Holarrhena floribunda	Stem bark	Concosine and total alkaloid	+	+			+	D	+	
<u>Hodnoosrous</u> Intraii	Seeds	Fixed oil, hydno- carpio acid		+			+		*	
Hrdnoosrous victions	Seeds	Chaulmoogric acid								
HYDROYARUS SP.	Root	Hyosoyamine and other alkaloids		+	•				•	
Linnia obevetiari	Whole plant	Camphor and essen- tial oil		+	+				• •	51
Lobelia promidelia	Leaf, flowering top	Lobeline and total extract		•			•	3	•	
Maniha sp. (Japanese mint) Maniha piperita	Whole plant	Insential oil	•		+	+	•		** **	8
Incuna pruriens	Beans	1-Dopa	+	+	٠	•	+	3	+ +	•
Oncobe echinata	Seeda	Fixed oil			+				+	
Papaver somiferum	Capsule and latex	l Morphine, codeine moscapine papaverin	ie +			+	+	D	++ +4	U
Passiflors sp.	Whole plans	Total extract	+	+	+	+	+	C	+ +	1
Pausinystalia rohimba	Stem bark	Yohimbine and total extract		•	•			3	+ +	1
Physostians Ysbabaris	Seeds	Physostigmine, stignasterol		+	+			2	+ +	. 1
Physochlaine presite								¢,D		
Pilocerne #p.	Leaves	Pilocerpine		•		+		>	• •	- 1

¥...

Annes I (Cont*d)

	Part of the plant		Availa Julti-	bility		Region		Nethod of produc-		rket mtial	
Name of plant	used	Product	vated	Wild	Africa	America	Asia			Export	Trend
Plantago ovata	Seeds, husks	Ispaghula, psyllium	+				+		++	++	Up
Podophyllum hex- andrum (Peemodi)	Tubers	Podophyllin, podo- phyllotoxin		+			+	D	+	++	
Polygala senega	Roots	Resin		+	+				+	+	Up
Prunue africana	Stem bark	Total extract		+	+			C	+	++	Steady
Peoreles corylifolia	Seeds	Psoralen		+			+	D	+	+	Steady
Rauwolfia heterophylla serpentina Nauwolfia yomitoria	Roots	Recerpine, ajmaline, decerpidine, rescinnamine, recerpiline		•	•			Ð	•	•	Up
Phamnus	Bark	Crude extract				•		c	•	+	Steady
purshiana	Rhizome	Total extract	•	Ţ		Ŧ		c			Steady
Nhoum emodi	Rhizome	Total extract	*	+ +	Ť		Ĭ	c	Ť	+	Steady
Rheum palmatum	Seeds	Fixed oil	Ţ	Ţ		•	Ţ	•		++	Steady
Ricinus communis		Solasodine	Ţ	Ī	Ţ	Ţ	Ī	D		**	
Solanum sp.	Berries		•	-	•	•	•	•	•	•	
Steroulis setigers	Bark erudate	Crum		+	•		٠		+	+	Steady
Strophanthus gratus	Seeds	Strophanthine, etrophanthidine		+	•			D	+	+	Up
Strophanthus kombe											
Strychnos nux vomica	Seeds	Stryohnine		+	•		+	Э	+	+	Steady
Tabermanth iboga	Stem bark	Ibogaine		+	+			D		+	
officinale	Root	Resin and total extract		+		+	+	D	+	+	Steady
Thevetia neriifolia	Seeds	Peruvoside	+		•	•	+	D	+ '	+	Steady
Urgines indics) Urgines scills)	Bulbs	Proscillaridine		+	•	٠	+	C	+	+	Steady
Valeriana officinalis Valeriana walichii	Rhizome	Total extract	•	+		•	+	C	+	•	81 oadş
Voscanga thoursii Voscanga africana	Seed	Tabersonine		•	•			3		+	Up
Vince minor	Leaves	Vincemine	•	+	•	+	+	ъ	+	+	Up

Contraction and States

.

·•

Annex II

ADDITIONAL LIST OF PLANTS USED MAINLY IN TRADITIONAL MEDICINE IN APRICA, ASIA AND LATIN AMERICA

Name of plant	Part of plant used	Type or use of drug
Acacia catechu		For ulcers, beils, indiges- tion and throat pain
Acacia senegal	Cross	In diarrhoea
Aconitum heterophyllum		Antiperiodic, antidiarrhoeal, antirheumatic
Achyranthus aspera		In leprosy
Acorus calasus		Antispamodic, carminative, antitussive
Adansonia digitata		Antidiarrhoeal
Adhatoda vasica		Antitussive
Adonsonia digitata		
Aegle marmelos		Antipyretic, stomachic, antidiarrhoeal
Alchornes cordifelis		Antimalarial
Allium sativum	Bulb	Anti-infectious
Alce barbadensis		
Alpinia galanga	Thisone	Anti-infectious
Alpinia siamensis	Rhisome	Anti-infectious
Alstonia scholaris		Antimalarial, febrifugal, antidiarrhoeal
Althoca officinalis		Antidiarrhoeal, antidysenteric
Amonum xanthoides		For tincture of cardmon , antitussive
Anacardium occidentale	Bark	Antidysenterio
Andrographis paniculata	Plant	Antidysenterio
Anisomeles ovata		Carminative
Annona muricata		
Areca catechu	Seed	Anti-infectious
Artemisia abiutlium	Flower	
Artemisia herbealba		
Asiacuosi asu		Antinalarial

· · ·

Name of plant	Part of plant used	Type or use of drug
<u>Asiacuosi dec asfarms moris</u> (fresh)		Anthelminthio
Asparagus racemosus	Root	Ant idysenteric
Asparagus racemosus		Refrigerant, diuretic, antidiarrhoeal
Atrocarpus lakolcha	Bark	Anthelmint hio
Averrhoa carambola	Flower	Anthelmint hio
Azadirachta indica	Bark	Antinalarial
Azadirachta indica	011	Antiseptic; in rheumatism
Balicspermum montanum		Antifilarial
Bauhinia malabarica	Plant	Ant idysenterio
<u>Bergenia ligulata</u>		In fever, diarrhoea and pulmonary infection
<u>Berberis aristata</u>)		To diameters and downades
Berberis asiatice		In diarrhoes and joundice
Bidens fuloss		
<u>Bidens pilosa</u>		Ant imicrobial
<u>Blumea balsamifera</u>		As camphor
Boarhavia diffusa		Hypertensive, antidiuretic
<u>Boerrhavia diffusa</u>		In uterine bleeding
Butes frondosa		Anthelminthio
Carrophyllus aromaticus		For toothache; carminative
Carthanus tinctorius	Flowers	Stimulant
<u>Carum copticum</u> (Ajowan)	Fruit	Stomachic, carminative
Cassia tistula		Laxative
Catharanthus roseus		
Celosia argentea	Seed	Anthelmint hio
<u>Centella asiatica</u>		In skin di seases
Cephaelis ipecachuana		In amoebiasis
Chenopodium ambrosiodes		Bilassia
Cimunum cyminum	Pruit	Ant helmint hic
Cinchona sp.		Antimalarial

•

- 27 -

Name of plant	Part of plant used	Type or use of drug
Cinnemcaum camphora		For rheumatian
Cinnamonum inuctum	Leaf oil	Antidiarrhoeal
Cimmamonum tamala	Bark	Aromatio, stomachic
Citrus aurantifolia	Root	Antidysenteric
Cleomechlidonii	Root	Anthelminthic
Clove		Carminative, stomachic
Coleus kilimanosohari		Ant imicrobial
Coptis tecta	Rhisome	Tonic, antidiarrhoeal, ophthalmic
Cucurbita peps	Seeds	Anthelmint hic
Curculigo orchioides		For asthma, gonorrhoea; as diuretic and tonic
Curcuma como sa	Rhische	Blood circulation regulator
Cyperus rotundus	Bulb	Anti-infectious
Cyperus scariosus		Antidiarrhoeal, anti- inflammatory
Datura fostusa Datura strancaium Derris pinnatus		Antinalarial
Degnodium gangeticum	Root	Astringent, tonic
Demodium triflorum	Plant	
Dipterocarpus tuberculatus	Resin	For ulcers
Inbelia ribes		Arthelmint hic
Ephedra gerardiana		Antiasthmatic; for inflamma- tion of bronchi
Furenia cumini	Bark	2
Bucenia jambos	Beed	Antidysenteric
Bugenia malaccensis	Bark	ι.
Bupetorum odoratum	Herb	Haemost at ic
Suphorbis thusifolis		Antidysenteric
Perula foelida		For gastric disorders

Name of plant	Part of plant used	<u>of drug</u>
Garcinia pedunculata	Dried fruit	For indigestion
Gentiana kurroo	Rhisome	Bitter tonic
Gentiana sp.		Ant ipyretio
<u>Glycyrrhiza glabra</u>		Colitis
Gremmatophyllum speciosum	Bulb	Ant helminthic
Hagenia abbysinoa (Taenia, Botigocephalus)		For ophthalmic disorders of children
Heliotropum indioum	Herb	For ulcers; diurctic
Holarrhena antidysenterica	Bark	Antidysenteric
Ibosa riparia		Antimicrobial, antimalarial vermifuge
Iris nepalensis		Diuretio, in bilicus obstruction
Ixora cocceinea	Root	Ant i-infectious
Juniperus sp.	Pruit	
Lansium domesticum	Seed	Anthelminthic
Linaria remosissina		Ant inclarial
Lobelia pyramidalis		Antispamodi o
Mallotus philippinensis		Anthelminthic
Matricaria chancuila		
Nelia asadarach	Leaves	Anthelminth io
Mentha citrata		
Nesua ferrea		Stomachic, expectorant, paste for bites
Nillingtonia hortensis		For hypertension
Minosa pudioa	Leaves, roots	For haemorrhoids
<u>Mirabilis islapa</u>		Wound dressing
Nomordica charantia		Hypoglyarioht
Murraya paniculata	Leaves	Anthelminthi o
Mustard		Oil for massage and ointments
Myristics fragrans		Carminative; for nauses and
		vomiting

- 29 -

٠,

.

Name of plant	Part of plant used	Type or use of drug				
Nardostachys jatamansi		Carminative; for cholera and hysteria				
Nutmeg		Carminative, stomachic				
Ocimum basilicum		Antidysenteric				
Ocimum sanctum		Hypoglycemic, expectorant				
<u>Orchis lanata</u>		Tonic				
Pandanus odorus	Leaves (fresh)	Anti-infectious				
Perezia cuernavacana	Roots	Antitumoral				
Phyllanthus emblica		Refrigerant, diurstic and laxative				
Phyllanthus madraspatensis		Antidysenteric				
Picrorhiza scrophularaifolia		Antipyretic, stomachic				
Pinus sp.	Resin	Carminative, expectorant; in asthma and bronchitis				
Piper betle	Leaves	Anti-infectious				
Piper nigrum		Stomachic, antitussive				
Piper longum		Antifilarial, antipyretic				
Piper longum	Rhisome	Stimulant, tonic				
Plantago major		Antidysenteric				
Plumbago rosea	Root	Stimulant in rheumatism				
Plumbago zevlanica		Antifilarial				
Podophyllum hexandrum		For liver and gall bladder				
Portulaca oleracea	Leaves	Anti-infectious				
Pousolsia pentandra	Leaves	Anti-infectious				
Punica granatum	Pruit	Anti-infectious				
Quisualis indica	Seed	Anthelmint hio				
Rauwolfia serpentina		Hypnotic, sedative, hyper- tensive				
Rheum emodi		Purgative; in diarrhoea				
Rhus vulgaris		Hemnionoides				
Rubia cordifolia		For leprosy				

- 30 -

Name of plant	Part of plant used	Type or use of drug
Sapindus mukrolli		Spermioidal
Securidace longipedunoculate		Nolluscicidal
Securinega vircsa		Polyvalent
Smilax peguana	Rhische	Antisyphilitic
Stemona collinsae))	
Stemona curticli	{	
Stemona minor	Plant {	Anthelminthic
Stemona tuberosa	{	
Streblus asper	Seed, bark	Anti-infectious
Strophanthus samentoms		Trastone, sactone
Swertia chirata		Antimalarial, antipyretic,
Swertia moorcroftiana)		anti-infectious; for diarrhoea, jaundice
Tamarindus indica	Pulp	Laxative
Taraxacum officinalis		Diuretic; for chronic
		disorders of kidney and liver
Terminalia arjuna		
Terminalia belerica		Lazative, antipyretio; for
		dropsy, haemorrhoids
Terminalia belerica	Fruit	Bitter tonic, astringent
Terminalia chebula		Antidysenteric
Thapsia garganica		Rubefiant
Tinospora cordifolia	Plant	Anthelminthic
Tinospora cordifolia	St en	In diabetes
Trachespermum ammi		Antispamodic; in cholera
Valeriana walliohii		Carminative; in nervous disorders
Vernonia amygdalina		Vermifugal, antiviral
Veronia anthelminticum		Anthelminthic
Veronia cinerea		Antifilarial, antipyretic
Viter glabrata	Leaves	In diabetes
Zanthoxylum armatum		In dyspepsia and cholera
Zingiber officinalis		Antidysenterio
		- -

- 31 -

• •

Amex III

INFORMANT PLANT DRUCS SUITABLE FOR PRODUCTION BY DEVELOPING COUNTRLES

		Beential	Second .	Second category
Therepeutic Group	Plant	Active constituent	Plant	Active constituent
Anaesthetics	ŧ		ſ	I
Analgesics, antipyratics,	Papaver somniferus	Morphine Codeine	Aesculus Etypocastamus Aesculus indica	Asscine and total extract
Nonsteroidal anti-inflammatory drugs and antigout drugs	Gloriosa superba	Colchicine		- 3
Antiallergics	I	ŧ	I	1
Antidotes, chelating agents, cholagogue			Combretum ad creat thus	Extract
Anti-epileptics	l		ł	1
Anti-infective Antiprotozoal	Cephaëlis ipecacuanha Cinchoma sp.	Buetine Quinine	11	
Anthelminti c	1 1	1 1	Chemopodium ambrosioldes Artemisia maritima	Ascaridol, total extract Santonin
Antimigratue	Claviceps purpures	Ergotanine	I	I
Antineoplastic	Catharanthus rosqua Catharanthus lanceus	Vinblastine Vincristine	Podophyllum herandrum (P.emodi) Prunus africana	Podophyllotoxin and total extract Total extract (specific for prostate enlargement)

,

	1	beerpidin	Lynne Yangi				Strophanthus gratus Strophanthin Thevetia narifolia Peruvoside Urginea scilla Proscillaridine (Scilla maritime) Rutin or bioflavamoide	Psorales coryli- Psoralen folia	•	1		
1.00M	ł	Reacydue outproced	Instantas And	Vincentine		Quinidine A junitime	Digorin and Str lamatowides The - Urg	Xam thotoxin Peoral folia	Ariaticoride		Total alkaloide atropine or hunaceaine	
August and	1	Brueolfia serpentiae Brueolfia vontioria Brueolfia confereitonates	Cettarentine roome Cettarentine lanete		Voscenes africens a/ Voscenes thoursis a/	Cinchons sp. Remolfia sergenting and other stration	Distalis lamata	American particular	Centella aziatica	- Theobroms caceo	Duboisia myoporoidae Duboisia leichartii	Atropa belladonna Atropa acuminata Datura stramonium Datura stramonium Datura metel Hroscymmus niger Physochlaina premita
Antipartineoniem Wicod and heemicondetic	ayatan Gani manular	Antihypertexatve				An ti-arring the lo	Cartiotonic	Dermatological menunutione		Diagnostic agents Diurstics	Antispamodics	

Provides the material for drug production. ŧ

Total extract Aloim	fotal extract			1						Reserptine and crude extract Walepotriate and total extract
Allos sp.	Cerstonia siliana			ı						Reunolfia serpen- tima Reunolfia conferti- floratum Reunolfia vomitoria Reunolfia vomitoria Valeriana unilichii Valeriana offici- total extract nalis
Semosides mirture or semosides A,B	as such and pro- ducts gly cyrrhet ic acid and extract g Berberine	Diosgenin s/	Solasodine s/ Hecoginin s/	I	Physosti gaine	d-fubocurarine	Pilocarpine	Physostignine Atropine a/ (as homotropine)	Ergometrine	
Casaria encurtifolia Casaria italica Casaria ecutifolia	<u>Plantago oveta</u> Glycyrthiga glabra Berberis aristata	<u>Dioscorea deltoides</u> <u>Dioscorea floribunda</u> <u>Dioscorea composita</u> Costus speciosus	Solanum laciniatum Solanum khasianum Solanum xanthocarpum Agrve sisalana	I	Physostigne venenosum	Chondrodendron tomentosum	Pilocarpus sp.	Physostigma venenosum Duboisia myoporoides	Claviceps purpures	
Ca thar ti ca	Laratives Anti-ulcer Antidiarrhoeal	, seach of		Immologicals	Muscle Relements (peripherally soting) and antaconists	0	Oph thalmological		Orgetool ce	Prychotherapeutic

A Provides re .. meterial for drug production.

<u>Elycyrrhiss glabre</u> Total extract <u>Elycyrrhiss uraisn</u> sis	Glycyrrhiza vio- Laces	Glaucus flavus	Polygela sense. Total extract	1	1
Nyted rive		Theophylline s/ (as aminothylline)	Codetne	ı	1
Ephodre gerardians (Ephodre vulgaria)	Ethedre nebrodensis	Theobroms cacao	Papaver somiferun	I	ŀ
Brugs acting on the respiratory tract			·	Solutions correcting water, electrolyte, and acid-base disturbances	Vitatine and minerals

9 Provides was asterials for drug production.

Amex IV

- 36 -

OFTHER PLANTS OF ECONOMIC INFORTANCE AND EXPOSE FORMETAL

Accois seneral (A. Arebic) <u>Carica papays</u> Ananas <u>Chrysenthemum cinerarisefolium</u> <u>Cola nitida</u> <u>Comboporon flamiosus</u> <u>Derris elliptica</u> <u>Bucalyptus</u> sp. <u>Mentha</u> sp. <u>Passiflora</u> sp. <u>Ricimus communis</u> Soyabean (for sitosterol) <u>Steroulia estigura</u>

の市場のないので、「「「「「「「」」」」

たいというないではないたいないであるので、ないない

Sugar-cane press mud (for stignasterol)

Annex Y

BIOLOGICALLY ACTIVE PLANTS FOR WHICH DRUG DEVELOPMENT HAS REACHED AN ADVANCED STAGE

Plant	Part of plant	Properties
Annopa muricata	Seeds	Oxytocic
Alpinia siemensis	Rhische	Antibacterial, insect repellant
Adhatoda vasica	Leaves	Oxytocic
Asclepias curassavica	Seeds	Cardiotonic
Bruces marissins	Pruit	Anti-amoebic
Casiziros edulis	Seeds	Hypotensive
Chenopodium fostida C.Graveolens	Leaves	Antiparasitio
Coleus forshoklii	Roots	Hypotensive
Compiphora mukul	Resin	Hypolipidaemic
Derris trifolia	Root	Antispassodic
Echinops spinosus	-	Vasoconstrictor
Iponoea pescaprae	Plant	Antihistaminic, anabolic
Peretia hebeciada	Root s	Laxative
Ruta chalepensis	Leaves, sten	Oxytocic
Streblus asper	Seed	Antibacterial, antiseptic
Sepindus sukorosii	Seeds	Spermicidal
Sinciber Cassimunar	Rhische	Nuscle relaxant, analgesio

新井

Annex VI

THE IMPORTANT ENDIPINETS

Sterile products	Distilled water (sterile and pyrogen free)		
Sympe	Sugar syrup		
	Syrup Tolu		
	Syrup Auranti		
Oisteent	Lenolin		
	Petrol jelly		
	Cetosteryl alcohol		
	Nacrogog		
Suppositories	Gelatin, cacao butter		
Teblets	Starch, lactose		
	Microcrystalline cellulose		
	Polyvinyl pyrolidone		
	Shellac		
	Wax		
	Silicones		
Capsules	Gelatine		

Timotures and galemicals

10- 10- Mag

のためのないのでします

1000

ちちんないない

Aloohol

Annex VII

FACILITIES AVAILABLE IN VARIOUS COUNTRIES

AFRICA

ALGERIA

1	Laboratoire de matière medicale et pharmacologie	Phytochemistry
	Faculté de pharmacie	Pharmacology
	ALGIERS	

2 Laboratoire de recherche, développement et Galenique controle pharmacie centrale algerienne Analysis Lavigerie - EL HARRACH ALGIERS Control

BUYPT

- 1 Natural Research Center Phytochemistry Laboratory of natural products Dokki, CAIRO
- 2 Department of Pharmacognosy Faculty of Pharmacy, CAIRO

IVORY COAST

- 1 Institut ORSTON ADIOPODOUME
- 2 Laboratoire de botanique Laboratoire de chimie Faculté des sciences ABIDJAN

MADAGASCAR

1 Centre national de recherches pharmaceutiques TANANARIVE

NIGERIA

1 Institute of traditional medicine Paculty of Pharmacy University of IFE

Phytochemistry

Botan y Phytochemistry Pharmacology

Botan y Phytochemistry

Botan y Phytochemistry Pharmacology

Phytochemistry

SUDAN

1 National Industrial and Consulting Institute KHARTOUN

RNAN DA

1 Groupe de recherches pour la médecine traditionnelle, la pharmacopea et les plantes médicinales rwandaises Université nationale du Rwanda BUTARE

ABIA

THDIA

- 1 Central Drug Research Institute LUCINOW
- 2 Central Indian Nedicinal Plants Organisation, LUCKNOW
- 3 National Botanic Gardens, LUCKNOW
- 4 Regional Research Laboratory, Srinagar, KASHMIR

PARISTAN

 H.B.J. Postgraduate Institute of Chemistry, University of Karachi, KARACHI-32 Botany Phytochemistry Pharmacology

Botany

Chemistry Pharmacology Instrumentation Pharmaceuticals Process development Fermentation technology

Cultivation Propagation Collection Production

Plant breeding Tissue-culture methods for propagation of plants herbarium

Botany Chemistry Pharmacology

Centre for instrumentation (infrared, ultraviolet, nuclear magnetic resonance and mass spectrometry) Nioro-analysis General pharmacological screening

NIPAL

1	Department	of Medicinal	Plants
	Thapathali,	, KATHMAN DU	

- (a) Royal Drug Research Laboratory
- (b) Botanical Survey and Herbarium
- (c) Royal Botanical Garden
- (d) Herbal farms

THAILAND

1 Applied Scientific Research Corporation of Thailand (ASRCT) (Pharmaceutical Research Division) 196 Pahclyothin Road, Bangkhen, BANGKOK

2 Department of medical sciences Ministry of Public Health, Yosae, BANGKOK

LATIN MERICA

CUBA

1 Estacion Experimental de plantas medicinales, "Dr. J. T. Roig" Apdo, 33 Guira de Melena, HAVAMA

NUKI00

1 Instituto Nexicano Para El Estudio de Plantas Medicinales (INEPLAN) NEXICO 12 D.F. Phytochemical and pharmaceutical investigations

Plant identification

Germplasm centre for medicinal plants and seeds

Cultivation of Medicinal herbs and essential oil= bearing plants

Research work applied to drug industry

Basic research and routine investigation

For cultivation of plants

For ethnobotanical service and chemical and pharmacological investigation of plants

Annes VIII

LIST OF DOCUMENTS

1 3/10. 271/1	Plants of the African pharmacopoeias used in the treatment of tropical diseases J. Kerharo
I D/NO- 271/2	Industrial requirements for processing medicinal plants B. Bombardelli
19/10. 271/3	An integrated approach to research on medicinal plants N. Anand
1 3/W3. 271/4	Nedicinal plants for ouring diseases other than communicable, tropical and infectious P. Sandberg
13/10.271/5	List of participants

- 42 -

....

- 43 -


Annex IX

A NODEL UNIT FOR THE PREPARATION OF CRUDE EXTRACTS

The sequence of unit operations involved in processing 1 ton (t) of material per day is indicated in the flow chart below. Depending on the nature of the desired final product, the concentrate obtained can be processed further.

Only the major process equipment is shown in the flow chart. The complete list of equipment for the unit is as follows:

Item	Capacity	Innber required
Process equipment		
Circulation pump, etainlese steel, head 10 m	100 kg/h 1 500 l 500 l/h 3 000 l	1 1 5 8
Concentrator, etainless etcel, jacketed with agitator Shell-and-tube heat exchanger,	500 1	2
stainlese eteel, eurface area 2 m ² Receiver, stainlese steel Selvent recovery plant Filter Dryer	250 1	2 1 1 1 1
Service equipment		
Boiler, pressure 10 bar Vacuum pump, water-ring type, vacuum up to 0.06 bar Chilled-water circulation unit	300 kg/h 80 m ³ /h 20 t	1 2 1
Analytical instruments		
pH meter Thin-layer chromatography equipment with ultraviolet lamp Spectrophotometer, ultraviolet Centrifuge, laboratory model Soxhlet apparatus with bath Vacuum pump, cil Vacuum oven and muffle furnace Nicroscope		1 1 1 1 1 1 1



Flow chart for a multipurpose phytochemical processing plant

(ompacity 1 t/d)

MATIONAL INPONDATION CONTRE FOR DRUCK AND PRANMACEDITICALS (NICDAP)

FICINF is one of the four sectoral centres set up under the National Information System for Science and Technology (NISSAT) by the Department of Science and Technology, Government of India. This Centre is located at the Central Drug Desearch Institute, Lucknow.

Nission

KICDAP merves as a central information agency for collection, storage, retrieval and dissemination of information relating to drugs and pharmacouticals.

Usera

Scientists and technologists in R and D organisations and industry

Medical and veterinary colleges, schools of pharmacy, and university departments concerned with drug research

Management executives in the Central and State Governments responsible for health-care programmes

General information

MICDMP has its base at the CDMI Library, which subscribes to 350 national and foreign periodicals covering all scientific disciplines related to drug

Survey of Information Needs and Evaluation

Puturistic Studies

Industry

of Information Use

research. Some important foreign periodicals are airlifted. Secondary periodicals, including <u>Current Contents</u> <u>Chemical Abstracts, Biological Abstracts</u> <u>Chemical Abstracts, Biological Abstracts</u> <u>Science Citation Index, Scrip, Inpharme</u>, and <u>Tropical Diseases Bulletin</u> are also subscribed to. Back issues of periodicals are available in many cases from the very first issue. The total collection of the library numbers around 30,000 volumes, which include books, annuals, serials, advances, patents specifications, technical reports and bound volumes of periodicals. The CDRI Library uses the open-scoese system with self-explanatory catalogues.

Activities

WIGDAP activities consist of nine major projects:

Current Awareness Service R and D Industry Subject Bibliographies Patents Awareness Service New Drugs Bulletin Registry of Adverse Effects of Drugs Directory of Information Sources for Drugs Survey of Indian Drugs and Pharmaceuticels

Services and products

MICUMP issues three monthly bulletins:

Drugs and Pharmaceuticals:

Current Highlights (R and D)

Drugs and Pharmaceuticals:

Current Highlights (Industry)

Drugs and Pharmaceuticals:

Patents Awareness Bulletin

The Selective Dissemination of Information (SDI) service is also available.

Reproduction services include photocopying of documents available in the Centre (single copies for research purposes only).

A referral service directs the user to the source where information is available.

Printed in Austria Id.78-4000-January 1878-3,000

10/000 (10/00 271/0) 10 July 1070 0100 1011 ê

ので、「日本」の「日本」の「日本」を見ていた。 国家運動であ 「ないないとないないないないないないないない」ないできる AND BARN 「日本のないない」

.



81.10.23